Parkinson’s disease – pharmaceutical daily

September 23, 2019 Off

Cerevel Therapeutics happy with results from a Phase 2 study of Tavapadon in patients with early-stage Parkinson’s Disease

Cerevel’s study of Tavapadon results demonstrated a statistically significant improvement in motor symptoms with once-daily dosing of oral tavapadon, which has enabled the company to plan on kicking off Phase 3 trials of tavapadon to fully characterize its potential benefit for patients with Parkinson’s disease.

September 20, 2019 Off

Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai get approval of Safinamide for Parkinson’s Disease in Japan

By BusinessWire

Italian biopharmaceutical specialist for nervous diseases solutions, Newron Pharmaceuticals, and it’s partners Meiji Seika Pharma together with Eisai, got approval to produce and sell Equifina tablets in Japan.

September 19, 2019 Off

Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson’s Disease

By BusinessWire

Cerevel Therapeutics is expecting to presented data from studying Tavapadon in patients with early-stage Parkinson’s Disease, at the 2019 International…

March 22, 2017 Off

FDA OK’s Parkinson’s disease drug

By Dino Mustafić

The U.S. Food and Drug Administration has approved Newron Pharmaceuticals’s Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa.